| Attribute |
Value |
| 52 Week Change |
-0.52 |
| Address1 |
9,605 Medical Center Drive |
| Address2 |
Suite 270 |
| All Time High |
262,500.0 |
| All Time Low |
0.16 |
| Ask |
0.0 |
| Ask Size |
3,500 |
| Average Daily Volume10 Day |
4,521,320 |
| Average Daily Volume3 Month |
21,206,804 |
| Average Volume |
21,206,804 |
| Average Volume10Days |
4,521,320 |
| Beta |
1.095 |
| Bid |
0.2291 |
| Bid Size |
5,000 |
| Book Value |
0.336 |
| City |
Rockville |
| Compensation As Of Epoch Date |
1,767,139,200 |
| Country |
United States |
| Crypto Tradeable |
0 |
| Currency |
USD |
| Current Price |
0.234 |
| Current Ratio |
1.633 |
| Custom Price Alert Confidence |
HIGH |
| Date Short Interest |
1,782,777,600 |
| Day High |
0.2389 |
| Day Low |
0.2251 |
| Debt To Equity |
23.982 |
| Display Name |
Theriva Biologics |
| Dividend Date |
1,534,118,400 |
| Earnings Call Timestamp End |
1,711,369,800 |
| Earnings Call Timestamp Start |
1,711,369,800 |
| Earnings Timestamp End |
1,755,174,600 |
| Earnings Timestamp Start |
1,755,174,600 |
| Ebitda |
-12,624,000 |
| Ebitda Margins |
0.0 |
| Enterprise To Ebitda |
-0.0 |
| Enterprise To Revenue |
0.003 |
| Enterprise Value |
884 |
| Eps Current Year |
-0.2 |
| Eps Forward |
-0.2 |
| Eps Trailing Twelve Months |
-0.58 |
| Esg Populated |
0 |
| Exchange |
ASE |
| Exchange Data Delayed By |
0 |
| Exchange Timezone Name |
America/New_York |
| Exchange Timezone Short Name |
EDT |
| Fifty Day Average |
0.2894 |
| Fifty Day Average Change |
-0.055400014 |
| Fifty Day Average Change Percent |
-0.19143058 |
| Fifty Two Week Change Percent |
-52.0 |
| Fifty Two Week High |
0.86 |
| Fifty Two Week High Change |
-0.62600005 |
| Fifty Two Week High Change Percent |
-0.727907 |
| Fifty Two Week Low |
0.16 |
| Fifty Two Week Low Change |
0.074 |
| Fifty Two Week Low Change Percent |
0.4625 |
| Fifty Two Week Range |
0.16 - 0.86 |
| Financial Currency |
USD |
| First Trade Date Milliseconds |
1,166,452,200,000 |
| Float Shares |
45,143,241 |
| Forward Eps |
-0.2 |
| Forward P E |
-1.17 |
| Free Cashflow |
-4,870,250 |
| Full Exchange Name |
NYSE American |
| Full Time Employees |
15 |
| Gmt Off Set Milliseconds |
-14,400,000 |
| Gross Margins |
1.0 |
| Gross Profits |
300,000 |
| Has Pre Post Market Data |
1 |
| Held Percent Insiders |
0.01633 |
| Held Percent Institutions |
0.043169998 |
| Implied Shares Outstanding |
45,892,668 |
| Industry |
Biotechnology |
| Industry Disp |
Biotechnology |
| Industry Key |
biotechnology |
| Ir Website |
http://www.syntheticbiologics.com/investors |
| Is Earnings Date Estimate |
1 |
| Language |
en-US |
| Last Fiscal Year End |
1,767,139,200 |
| Last Split Date |
1,724,630,400 |
| Last Split Factor |
1:25 |
| Long Business Summary |
Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. Its lead product candidate, VCN-01 (zabilugene almadenorepvec), a clinical stage oncolytic human adenovirus that is in Phase 1 clinical trials and Phase 2 VIRAGE trial for patients with pancreatic cancer, head and neck squamous cell carcinoma, ovarian cancer, colorectal cancer, and retinoblastoma. The company also develops VCN-11 for treating solid tumors; SYN-004 (ribaxamase), an oral capsule prophylactic therapy that is in Phase 1b/2a clinical trials for the prevention of acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT); and SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) for multiple gastrointestinal and metabolic indications. In addition, it develops clinical stage products, such as SYN-006 to prevent aGVH, clostridioides difficile infection, and microbiome damage in patients treated with carbapenem antibiotics; and SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics. The company has a license agreement with Rasayana Therapeutics, Inc. to research, develop, manufacture, and commercialize any product that includes SYN-020, as well as a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Theriva Biologics, Inc. is headquartered in Rockville, Maryland. |
| Long Name |
Theriva Biologics, Inc. |
| Market |
us_market |
| Market Cap |
10,738,884 |
| Market State |
PRE |
| Max Age |
86,400 |
| Message Board Id |
finmb_24424557 |
| Most Recent Quarter |
1,774,915,200 |
| Name Change Date |
2,026-07-13 |
| Net Income To Common |
-22,969,000 |
| Next Fiscal Year End |
1,798,675,200 |
| Non Diluted Market Cap |
11,101,436 |
| Number Of Analyst Opinions |
2 |
| Open |
0.231 |
| Operating Cashflow |
-14,369,000 |
| Operating Margins |
-7.09 |
| Payout Ratio |
0.0 |
| Phone |
301 417 4364 |
| Pre Market Change |
-0.0038000047 |
| Pre Market Change Percent |
-1.6323044 |
| Pre Market Price |
0.229 |
| Pre Market Time |
1,784,023,514 |
| Prev Name |
Synthetic Biologics, Inc. |
| Previous Close |
0.2419 |
| Price Eps Current Year |
-1.17 |
| Price Hint |
4 |
| Price To Book |
0.6964286 |
| Price To Sales Trailing12 Months |
35.79628 |
| Profit Margins |
0.0 |
| Quick Ratio |
1.58 |
| Quote Source Name |
Nasdaq Real Time Price |
| Quote Type |
EQUITY |
| Recommendation Key |
none |
| Region |
US |
| Regular Market Change |
-0.0079 |
| Regular Market Change Percent |
-3.26581 |
| Regular Market Day High |
0.2389 |
| Regular Market Day Low |
0.2251 |
| Regular Market Day Range |
0.2251 - 0.2389 |
| Regular Market Open |
0.231 |
| Regular Market Previous Close |
0.2419 |
| Regular Market Price |
0.234 |
| Regular Market Time |
1,783,972,800 |
| Regular Market Volume |
467,204 |
| Return On Assets |
-0.22600001 |
| Return On Equity |
-1.38911 |
| Revenue Per Share |
0.014 |
| Sand P52 Week Change |
0.20847368 |
| Sector |
Healthcare |
| Sector Disp |
Healthcare |
| Sector Key |
healthcare |
| Shares Outstanding |
45,892,668 |
| Shares Percent Shares Out |
0.0317 |
| Shares Short |
1,452,613 |
| Shares Short Previous Month Date |
1,780,012,800 |
| Shares Short Prior Month |
2,723,844 |
| Short Name |
Theriva Biologics, Inc. |
| Short Percent Of Float |
0.0317 |
| Short Ratio |
0.09 |
| Source Interval |
15 |
| State |
MD |
| Symbol |
TOVX |
| Target High Price |
4.0 |
| Target Low Price |
1.0 |
| Target Mean Price |
2.5 |
| Target Median Price |
2.5 |
| Total Cash |
14,431,000 |
| Total Cash Per Share |
0.314 |
| Total Debt |
3,693,000 |
| Total Revenue |
300,000 |
| Tradeable |
0 |
| Trailing Annual Dividend Rate |
0.0 |
| Trailing Annual Dividend Yield |
0.0 |
| Trailing Eps |
-0.58 |
| Trailing Peg Ratio |
None |
| Triggerable |
1 |
| Two Hundred Day Average |
0.2673 |
| Two Hundred Day Average Change |
-0.033300012 |
| Two Hundred Day Average Change Percent |
-0.12457917 |
| Type Disp |
Equity |
| Volume |
467,204 |
| Website |
https://therivabio.com |
| Zip |
20,850 |